Wednesday, May 20, 2026

#GLP-1

3 articles

Novo Nordisk Surges 25% in 30 Days as Market Rewards AI-Driven R&D Overhaul

Pharma Earnings & Stock Performance

Novo Nordisk Surges 25% in 30 Days as Market Rewards AI-Driven R&D Overhaul

Salvado•May 18, 2026

FDA Moves to Ban Compounded GLP-1 Drugs, Threatening TomorrowsRx Business Model

Healthcare & Pharma

FDA Moves to Ban Compounded GLP-1 Drugs, Threatening TomorrowsRx Business Model

ViaNews Editorial Team (Markets)•Feb 21, 2026

Pfizer Eyes GLP-1 Market Entry by 2028: What the Metsera Deal Means for Investors

Pharmaceutical Sector

Pfizer Eyes GLP-1 Market Entry by 2028: What the Metsera Deal Means for Investors

ViaNews Editorial Team (Markets)•Feb 18, 2026